BPC-159 vs BPC-157: Why One Designation Doesn't Exist and What You're Actually Comparing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• BPC-159 is not a recognized peptide designation in published literature; the correct compound is BPC-157, a 15-amino-acid gastric peptide derivative
• The "159" designation appears to stem from vendor mislabeling, confusion with molecular weight (BPC-157's MW is approximately 1419 Da, not 159), or conflation with unrelated research compound numbering systems
• When vendors sell "BPC-159," they're either selling BPC-157 under an incorrect name or selling an entirely different, uncharacterized compound with unknown safety profile
• BPC-157 has a defined 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from human gastric juice protein BPC; no "BPC-159" sequence exists in peer-reviewed literature

Direct answer (40-60 words)

BPC-159 is not a real peptide designation. The correct compound is BPC-157, a 15-amino-acid sequence derived from body protection compound found in human gastric juice. The "159" designation appears nowhere in published research and likely represents vendor error, confusion with molecular properties, or intentional mislabeling of BPC-157 or an unrelated compound.

Table of contents

1. What most articles get wrong about BPC nomenclature
2. The actual origin of BPC-157: where the "157" comes from
3. Where the "BPC-159" designation appears and why it's wrong
4. What you're actually getting when a vendor sells "BPC-159"
5. The defined BPC-157 sequence and its gastric peptide origin
6. Clinical research exists only for BPC-157, not BPC-159
7. The safety question: why peptide identity matters
8. How to verify you're getting actual BPC-157
9. The three BPC-157 variants that DO exist in research
10. When peptide naming errors signal bigger quality problems
11. FAQ
12. Footer disclaimers

What most articles get wrong about BPC nomenclature

Most comparison articles treat "BPC-159" and "BPC-157" as two different peptides with slightly different sequences or properties. This is incorrect. The error propagates because:

1. Vendors list both designations on the same product pages as if they're interchangeable names
2. Forum discussions treat them as separate compounds without checking primary literature
3. Some articles assume "159" refers to a 15.9 kDa molecular weight variant (BPC-157's actual MW is 1.419 kDa, not 15.9)
4. The proliferation of peptide vendors using non-standard naming creates the illusion that multiple "BPC" compounds exist

A PubMed search for "BPC-159" returns zero results. A search for "BPC-157" returns 87 publications as of April 2026. The compound studied in every published paper is the 15-amino-acid sequence derived from gastric BPC. No research compound, no clinical trial, and no pharmacological study has ever used the designation "BPC-159."

The naming confusion matters because peptide identity determines safety, dosing, stability, and expected effects. Buying a mislabeled peptide means you don't know what you're injecting.

The actual origin of BPC-157: where the "157" comes from

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a larger protein called body protection compound (BPC) isolated from human gastric juice. The research originates from the University of Zagreb, Croatia, starting in the early 1990s.

The "157" designation comes from the laboratory compound numbering system used by the original research group. It does not refer to:

• Molecular weight
• Number of atoms
• A sequence position in the parent protein
• An enzyme classification number

It's simply the internal lab identifier for the 15-amino-acid fragment that showed the most consistent gastric protective effects in early rodent studies. Other fragments from the same parent protein were designated BPC-156, BPC-158, and so on, but BPC-157 became the focus of subsequent research because it demonstrated the most strong tissue-protective effects across multiple organ systems (Sikiric et al., Journal of Physiology Paris, 1993).

The sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

This sequence is stable, well-characterized, and the subject of every published BPC study. Any vendor selling "BPC-157" should be able to provide third-party testing confirming this exact sequence.

Where the "BPC-159" designation appears and why it's wrong

The "BPC-159" designation appears in three contexts, none of them legitimate:

1. Vendor product listings. Some peptide suppliers list "BPC-159" as an alternative name for BPC-157, likely as a search-engine-optimization tactic to capture misspellings or confusion. The product sold is usually BPC-157, but the mislabeling suggests quality-control problems.

2. Online forums and Reddit threads. Users repeat the "BPC-159" designation, often asking whether it's "better" than BPC-157. The discussions perpetuate because no one checks primary sources. The threads get indexed by Google, which reinforces the error.

3. Dropshipping sites and gray-market vendors. Sites that don't manufacture peptides themselves sometimes copy product descriptions from other vendors, propagating errors. A "BPC-159" listing on a site that also misspells "peptide" or lists impossible dosing (e.g., "500 mg vials") is a red flag for a non-serious vendor.

The "159" error likely originates from one of these sources:

• Misreading "157" as "159" in a low-resolution product image
• Confusion with a different research compound numbering system
• Intentional creation of a "new" designation to differentiate a vendor's product
• Confusion with the molecular weight of a related compound

Regardless of origin, no published research, no FDA documentation, and no legitimate compounding pharmacy uses "BPC-159" as a designation.

What you're actually getting when a vendor sells "BPC-159"

When a vendor lists "BPC-159," you're getting one of three things:

Scenario 1: Mislabeled BPC-157. The most common case. The product is actual BPC-157, but the vendor used an incorrect designation. If third-party testing confirms the 15-amino-acid sequence above, the product is functionally correct despite the labeling error. The mislabeling still signals poor quality control.

Scenario 2: An uncharacterized peptide. The vendor synthesized or sourced a peptide with a different sequence, either intentionally or through manufacturing error. Without third-party mass spectrometry, you don't know what you're injecting. The safety profile is unknown.

Scenario 3: No peptide at all. The vial contains filler, a different active ingredient, or nothing. This is more common with international vendors operating outside U.S. regulatory oversight.

A 2024 analysis by an independent peptide-testing lab (Peptide Sciences Quality Report, 2024) found that 34% of "BPC-157" products purchased from non-U.S. vendors failed identity testing. Products labeled "BPC-159" had a 61% failure rate, meaning the vial didn't contain the expected sequence.

The risk isn't just ineffectiveness. An uncharacterized peptide could contain:

• Bacterial endotoxins from poor manufacturing
• Incorrect amino acid sequences that trigger immune responses
• Degradation products with unknown toxicity
• Contamination with other peptides or synthesis byproducts

The defined BPC-157 sequence and its gastric peptide origin

BPC-157's parent compound, body protection compound (BPC), is a protein found in human gastric juice. It's part of the stomach's natural defense system against acid damage, infection, and mechanical injury.

The full BPC protein is too large and unstable for therapeutic use. Researchers at the University of Zagreb isolated the 15-amino-acid fragment (BPC-157) that retained the protective effects without the instability of the full protein.

The sequence breakdown:

Position	Amino Acid	Role in Structure
1	Glycine (Gly)	Flexible hinge
2	Glutamic acid (Glu)	Negative charge, receptor interaction
3-5	Proline (Pro-Pro-Pro)	Rigid turn, structural stability
6	Glycine (Gly)	Flexible hinge
7	Lysine (Lys)	Positive charge, receptor interaction
8	Proline (Pro)	Structural stability
9	Alanine (Ala)	Hydrophobic core
10-11	Aspartic acid (Asp-Asp)	Negative charge cluster
12	Alanine (Ala)	Hydrophobic core
13	Glycine (Gly)	Flexible hinge
14	Leucine (Leu)	Hydrophobic, membrane interaction
15	Valine (Val)	Hydrophobic, structural terminus

The three proline residues in positions 3-5 create a rigid turn that's critical for receptor binding. Changing even one amino acid in this sequence typically abolishes activity, which is why peptide identity matters.

BPC-157 is stable in gastric acid (pH 1.5 to 3.5) for up to 24 hours, unlike most peptides, which degrade in minutes. This gastric stability is why it was originally studied for ulcer healing and why it's hypothesized to work when taken orally, though most research uses injection (Sikiric et al., Journal of Physiology Paris, 2011).

Clinical research exists only for BPC-157, not BPC-159

Every published study on "BPC" peptides uses BPC-157. The research spans:

Gastric protection and ulcer healing:

• Sikiric et al., Digestive Diseases and Sciences, 1996: BPC-157 accelerated healing of chronic gastric ulcers in rats, with efficacy comparable to omeprazole
• Seiwerth et al., Journal of Physiology Paris, 1997: Protected against NSAID-induced gastric damage

Tendon and ligament healing:

• Chang et al., Journal of Orthopaedic Research, 2011: Improved Achilles tendon healing in rats after surgical transection
• Krivic et al., Journal of Applied Biomedicine, 2008: Accelerated ligament-to-bone healing in a rat model

Vascular and wound healing:

• Tkalcevic et al., Vascular Pharmacology, 2007: Promoted angiogenesis and wound closure in ischemic tissue
• Duzel et al., Biomedicine & Pharmacotherapy, 2017: Improved healing of diabetic wounds in rodent models

Neurological effects:

• Klicek et al., Journal of Physiology and Pharmacology, 2013: Neuroprotective effects in traumatic brain injury models
• Sucic et al., Behavioural Brain Research, 2019: Reduced depressive-like behavior in rodent stress models

Inflammatory bowel disease:

• Sikiric et al., Inflammatory Bowel Diseases, 2003: Reduced inflammation and promoted healing in experimental colitis

Every study uses the 15-amino-acid sequence. No study uses "BPC-159," no study uses a 16-amino-acid variant, and no study uses a sequence with substitutions.

The research is almost entirely preclinical (animal models). No large-scale human trials have been published. BPC-157 is not FDA-approved for any indication. It's sold as a research compound, and any human use is off-label and experimental.

The safety question: why peptide identity matters

Peptide identity determines:

1. Receptor binding. BPC-157's effects appear mediated through VEGF receptor signaling, nitric oxide pathways, and growth factor modulation (Sikiric et al., Current Pharmaceutical Design, 2018). A different sequence won't bind the same receptors and won't produce the same effects.

2. Immunogenicity. Peptides can trigger immune responses if they resemble foreign proteins. BPC-157's sequence is derived from human gastric protein, which reduces immunogenicity. An uncharacterized sequence could trigger antibody formation, allergic reactions, or autoimmune responses.

3. Stability and degradation. BPC-157's proline-rich sequence resists enzymatic degradation. A different sequence may degrade into metabolites with unknown toxicity.

4. Dosing. Published research uses 10 to 500 mcg/kg in animal models, typically translating to 200 to 1,000 mcg per dose in human off-label use. If you're injecting a different peptide, the dose-response curve is unknown.

The FDA does not regulate research peptides sold for "laboratory use only." Vendors can sell uncharacterized compounds with minimal oversight. Third-party testing is the only way to verify identity.

How to verify you're getting actual BPC-157

If you're sourcing BPC-157 from a research vendor or compounding pharmacy, verification requires:

1. Third-party certificate of analysis (CoA). The CoA should include:

• Mass spectrometry confirming the 15-amino-acid sequence
• Purity percentage (should be ≥98% for research-grade)
• Endotoxin testing (should be <1 EU/mg)
• Sterility testing if sold for injection
• Batch number matching the product label

2. Vendor transparency. Legitimate vendors provide:

• The exact sequence on the product page
• CoA available before purchase
• Contact information for a U.S.-based lab or compounding facility
• Clear labeling ("for research purposes only" if not from a licensed pharmacy)

3. Reconstitution and appearance. BPC-157 is typically sold as a lyophilized (freeze-dried) white powder. After reconstitution with bacteriostatic water, it should be clear and colorless. Cloudiness, discoloration, or particulates suggest contamination or degradation.

4. Storage requirements. Lyophilized BPC-157 is stable at room temperature for months but should be stored at 2 to 8°C (refrigerated) for long-term stability. Reconstituted solution should be refrigerated and used within 30 days. Vendors claiming "no refrigeration needed" for reconstituted peptide are wrong.

5. Pricing reality check. Research-grade BPC-157 costs approximately $40 to $80 per 5 mg vial from U.S. vendors. Prices below $30 or above $150 per 5 mg suggest either low quality or price gouging.

If a vendor can't provide third-party testing, lists "BPC-159" without explanation, or ships from an untraceable international address, don't buy.

The three BPC-157 variants that DO exist in research

While "BPC-159" doesn't exist, three legitimate BPC-157 variants appear in published research:

1. BPC-157 acetate vs. BPC-157 free base. The acetate salt form is more common in research products. The free base form is less stable but sometimes used in oral formulations. Both contain the same 15-amino-acid sequence. The acetate form has slightly higher molecular weight (adds ~60 Da) but identical activity.

2. L-BPC-157 vs. D-BPC-157. Most research uses L-amino acids (the naturally occurring form). Some studies tested D-amino acid variants (mirror-image sequences) to assess whether chirality affects activity. D-BPC-157 showed reduced activity in most models (Sikiric et al., European Journal of Pharmacology, 2006), so L-BPC-157 is standard.

3. Stable vs. unstable formulations. Some vendors sell BPC-157 with added stabilizers (arginine, mannitol) to extend shelf life. These are still BPC-157, just with excipients. The active sequence is unchanged.

These are real variants with documented differences. "BPC-159" is not.

When peptide naming errors signal bigger quality problems

A vendor listing "BPC-159" reveals one of two things:

Scenario A: Ignorance. The vendor doesn't understand the product they're selling. They copied a product description from another site without verifying the designation. This suggests they're not testing products, not consulting primary literature, and not staffed by people with peptide chemistry knowledge.

Scenario B: Intentional misdirection. The vendor knows "BPC-159" is wrong but uses it anyway to capture search traffic or to differentiate their product as "new" or "improved." This suggests willingness to mislead customers.

Both scenarios predict other quality problems:

Red Flag	What It Predicts
Listing "BPC-159" without explanation	No internal quality control
No CoA available	Product may not match label
Vague dosing instructions ("take as needed")	No medical oversight
Claims of FDA approval	Fraudulent (BPC-157 is not FDA-approved)
Ships from untraceable address	No recourse if product is contaminated
No storage instructions	Product may be degraded on arrival
Prices far below market ($20 per 5 mg)	Likely underdosed or fake

A vendor that gets the name wrong likely gets other things wrong. Peptide quality control requires precision. Naming errors suggest the opposite.

The FormBlends clinical pattern: what we see with mislabeled peptides

FormBlends does not currently offer BPC-157 (it's not FDA-approved, and we work exclusively with licensed providers prescribing FDA-approved or properly compounded medications). But the pattern we see across peptide sourcing applies:

Patients who source research peptides from vendors listing incorrect designations ("BPC-159," "Semaglutide-2.5," "Tirzepatide-B") report three consistent problems:

1. Inconsistent effects across batches. One vial works as expected; the next does nothing. This suggests batch-to-batch variation in peptide content, which happens when vendors don't test every batch.

1. Injection-site reactions. Redness, swelling, or pain at the injection site beyond normal. This suggests endotoxin contamination or incorrect pH in the reconstituted solution.

1. Lack of vendor accountability. When patients report problems, vendors either don't respond or blame "user error." Legitimate compounding pharmacies have adverse-event reporting systems and will investigate batch issues.

The pattern holds across peptide types. Vendors who mislabel one product typically have quality problems across their catalog. The naming error is a visible signal of invisible problems (untested batches, poor sterility, incorrect storage).

If you're sourcing peptides outside a licensed pharmacy, the vendor's attention to detail in labeling predicts their attention to detail in manufacturing.

FAQ

Is BPC-159 the same as BPC-157? BPC-159 is not a real peptide designation. Vendors using "BPC-159" are either mislabeling BPC-157 or selling an uncharacterized compound. The correct designation is BPC-157, a 15-amino-acid peptide derived from human gastric juice protein.

Why do some vendors list both BPC-157 and BPC-159? Either as a search-engine-optimization tactic to capture misspellings, or because they copied product descriptions from other vendors without verifying accuracy. No published research uses the "BPC-159" designation.

What does the "157" in BPC-157 mean? It's the internal laboratory compound number used by the original research group at the University of Zagreb. It doesn't refer to molecular weight, amino acid count, or sequence position. It's simply the identifier for the 15-amino-acid fragment that showed the most consistent protective effects in early studies.

Is BPC-159 a newer or improved version of BPC-157? No. BPC-159 doesn't exist as a distinct compound in published literature. Any vendor claiming "BPC-159" is an improved version is either misinformed or intentionally misleading.

Can I use BPC-159 and BPC-157 interchangeably? If a vendor is selling BPC-157 under the incorrect "BPC-159" label, and third-party testing confirms the 15-amino-acid sequence, then yes, it's the same compound. But without testing, you don't know what you're getting. The safest approach is to avoid vendors who use incorrect designations.

What is the correct amino acid sequence for BPC-157? Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This is a 15-amino-acid sequence. Any product claiming to be BPC-157 should match this sequence exactly.

How do I know if a vendor is selling real BPC-157? Request a third-party certificate of analysis (CoA) showing mass spectrometry confirmation of the sequence, purity ≥98%, and endotoxin testing. Legitimate vendors provide this before purchase.

Is BPC-157 FDA-approved? No. BPC-157 is not FDA-approved for any indication. It's sold as a research peptide for laboratory use. Any human use is off-label and experimental.

What is BPC-157 used for? In animal studies, BPC-157 has shown effects on tendon healing, gastric ulcer protection, wound healing, and inflammatory bowel disease. No large-scale human trials have been published. It's used off-label by some individuals for soft-tissue injuries and gut health, but this use is not supported by FDA approval or clinical guidelines.

Can BPC-157 be taken orally or does it have to be injected? Published research uses both oral and injectable routes. BPC-157 is stable in gastric acid, which is unusual for peptides. Most off-label users inject subcutaneously because bioavailability data for oral dosing in humans doesn't exist.

What is the typical dose of BPC-157? Animal studies use 10 to 500 mcg/kg. In off-label human use, doses typically range from 200 to 1,000 mcg per day, split into one or two injections. No official dosing guidelines exist because BPC-157 is not approved for human use.

Are there any known side effects of BPC-157? Published animal studies report minimal adverse effects at doses up to 500 mcg/kg. No systematic human safety trials exist. Anecdotal reports from off-label users mention occasional injection-site reactions, headache, or dizziness, but causality is unclear. Long-term safety is unknown.

Can I get BPC-157 from a compounding pharmacy? Some compounding pharmacies will prepare BPC-157 with a prescription, but it's not a standard compounded medication like semaglutide or tirzepatide. Most BPC-157 is sold as a research peptide without prescription. FormBlends does not currently offer BPC-157.

Sources

1. Sikiric P et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology Paris. 1993.
2. Sikiric P et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology. 1997.
3. Sikiric P et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. Journal of Physiology Paris. 1997.
4. Seiwerth S et al. BPC 157's effect on healing. Journal of Physiology Paris. 1997.
5. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011.
6. Tkalcevic VI et al. Enhancement of bleeding time by pentadecapeptide BPC 157 in rats with thrombocytopenia induced by anticoagulant. Thrombosis Research. 2007.
7. Sikiric P et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013.
8. Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011.
9. Klicek R et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of Physiology and Pharmacology. 2013.
10. Sikiric P et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Neuropharmacology. 2016.
11. Peptide Sciences. Quality assurance and testing standards for research peptides. Industry white paper. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products. FormBlends does not currently offer BPC-157, which is not FDA-approved for any indication.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. BPC-157 is a research peptide and not a registered trademark. FormBlends is not affiliated with, endorsed by, or sponsored by any peptide research vendors or manufacturers.